In Segment C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Members will obtain treatment until condition progression or even the individuals are unable to tolerate the study drugs. Ubiquitin-connected proteins that regulate The steadiness of critical super enhancer-mediated proteins have also https://abbv-744-in-acute-myeloid02467.loginblogin.com/39132589/abbv-744-cancer-treatment-clinical-trials-an-overview